Vertex executives defend IgA nephropathy kidney drug ahead of FDA decision
On an earnings call, Vertex expressed conviction in the coming launch of povetacicept, viewed as important to its future.
Read at Biopharmadive โFull coverage ยท 7 outlets
- Biopharmadive ยท lead
- Yahoo FinanceVertex, ahead of FDA decision, calms fears surrounding kidney drug
- BioSpaceVertex opens up larger kidney disease opportunity with mid-stage readout
- STATFDA approves Vera Therapeutics kidney disease treatment | STAT
- BioPharma DiveVertex kidney disease drug hits mark in late-stage study
- Vertex Pharmaceuticals Newsroom(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
- MSNVertex slumps on light pain drug sales, but a key kidney catalyst lies ahead